×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| AJANTA PHARMA LTD. | 12491.9 | 2549.7 | 12085.6 | 20.4 | 32,232 | 34.7 |
| Krishna Institute of Medical S | 3856.0 | 588.0 | 3734.0 | 1.47 | 30609 | 83.0 |
| Dr. Lal Pathlabs Limited | 6670.0 | 1293.0 | 6407.0 | 15.49 | 27303 | 53.2 |
Ajanta Pharma Ltd., with Security Code 532331, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 848.9 | 1,014.6 | 945.2 | 1,085.3 | 926.1 | 1,077.3 | 1,128.9 | 1,101.9 | 1,013.9 | 1,208.6 |
| Expenses | 704.3 | 737.7 | 671.5 | 758.1 | 698.9 | 761.4 | 826.0 | 765.6 | 764.3 | 879.2 |
| Operating Profit | 144.5 | 276.9 | 273.7 | 327.2 | 227.2 | 315.8 | 302.9 | 336.3 | 249.7 | 329.4 |
| OPM % | 17.03% | 27.29% | 28.95% | 30.15% | 24.53% | 29.32% | 26.83% | 30.52% | 24.62% | 27.26% |
| Other Income | 36.8 | 31.5 | 52.2 | 13.7 | 33.7 | 28.4 | 40.3 | 33.2 | 17.9 | 40.6 |
| Interest | 1.2 | 0.8 | 2.3 | 2.4 | 1.4 | 0.7 | 0.7 | 2.5 | 0.7 | 0.7 |
| Depreciation | 32.1 | 32.2 | 33.0 | 33.4 | 33.5 | 32.9 | 33.3 | 34.9 | 38.8 | 40.3 |
| Profit before tax | 148.0 | 275.4 | 290.5 | 305.1 | 225.9 | 310.6 | 309.2 | 332.2 | 228.2 | 329.0 |
| Tax % | -20.8% | -23% | -26.9% | -27.9% | -28% | -24% | -24% | -24% | -15.2% | 22.5% |
| Net Profit | 117.2 | 212.0 | 212.4 | 220.2 | 162.7 | 236.0 | 235.0 | 252.5 | 193.4 | 255.0 |
| EPS in Rs | 9.15 | 16.84 | 16.85 | 17.47 | 12.91 | 18.75 | 18.74 | 20.15 | 0 | 20.4 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 971.8 | 881.8 | 1,021.0 | 1,028.4 | 1,105.2 | 1,054.1 | 1,144.9 | 1,186.6 | 1,146.1 | 1,170.4 |
| Expenses | 802.2 | 732.5 | 749.7 | 737.8 | 791.1 | 775.8 | 814.6 | 875.5 | 825.3 | 873.3 |
| Operating Profit | 169.6 | 149.4 | 271.3 | 290.7 | 314.1 | 278.3 | 330.4 | 311.2 | 320.8 | 297.2 |
| OPM % | 17.45% | 16.94% | 26.57% | 28.26% | 28.42% | 26.4% | 28.85% | 26.22% | 27.99% | 25.39% |
| Other Income | 34.9 | 36.8 | 31.8 | 21.3 | 13.6 | 35.5 | 26.5 | 19.5 | 30.4 | 18.1 |
| Interest | 2.8 | 1.1 | 0.9 | 2.3 | 2.5 | 1.5 | 0.7 | 6.0 | 7.9 | 6.1 |
| Depreciation | 33.3 | 33.0 | 33.2 | 33.7 | 34.3 | 34.3 | 34.0 | 34.4 | 36.0 | 39.8 |
| Profit before tax | 168.3 | 152.1 | 269.0 | 275.9 | 290.9 | 278.0 | 322.1 | 290.2 | 307.4 | 269.4 |
| Tax % | -20.1% | -19.6% | -22.6% | -29.2% | -27.8% | -27.1% | -23.7% | -25.4% | -24.2% | -16.4% |
| Net Profit | 134.5 | 122.3 | 208.1 | 195.3 | 210.0 | 202.7 | 245.8 | 216.5 | 232.9 | 225.3 |
| EPS in Rs | 10.5 | 9.54 | 16.53 | 15.5 | 16.67 | 16.09 | 19.53 | 17.26 | 18.59 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 15% |
| 3 Years: | 11% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 16% |
| 3 Years: | 8% |
| TTM: | 15% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 21% |
| 3 Years: | 31% |
| 1 Year: | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 12% |
| 3 Years: | 12% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 9% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 21% |
| 3 Years: | 31% |
| 1 Year: | 7% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|